Stocks · News reference
BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October
Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell LinesPresentation #: 1435ePPresentation type: e-PosterLocation: e-Poster
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioLineRx shares are trading lower after the company announced a $3.75 million offering of ADSs at $2.78 each.
BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that